Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to ...

Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $432.00. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful in ...

J.P. Morgan analyst initiated coverage with a Hold rating on Amgen today and set a price target of $300.00. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful inves ...

Amgen (AMGN) faces a U.S. withdrawal of its rare disease therapy Tavneos due to safety concerns and a potential manipulation ...

Amgen (AMGN) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $4.73 per share. This compares to earnings of $4.9 per share a year ago. These figures are ...

For the quarter ended March 2026, Amgen (AMGN) reported revenue of $8.62 billion, up 5.8% over the same period last year. EPS came in at $5.15, compared to $4.90 in the year-ago quarter. The reported ...

TheFly reported on April 9 that Guggenheim increased its price target on AMGN from $347 to $351 while maintaining a Neutral ...

This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts feature). Let's look at the situation in ...

Amgen’s (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in ...